-
January 17, 2023Umecrine Cognition announces Orphan Drug Designation granted by FDA for golexanoloneSTOCKHOLM – January 17, 2023. Umecrine Cognition AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
-
January 9, 2023Umecrine Cognition will attend the JP Morgan 41st Annual Healthcare Conference 2023 in San FranciscoSTOCKHOLM – January 9, 2023. Umecrine Cognition today announces that the company will attend the JP Morgan 41st Annual Healthcare Conference in San...
-
January 3, 2023Umecrine Cognition presents data showing improved symptoms in a model of Parkinson’s disease following treatment with golexanoloneStockholm, January 3, 2023 – Umecrine Cognition AB today announced results showing that the company’s clinical drug candidate golexanolone...
Subscribe
Our drug projects

GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.